These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26059485)

  • 1. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
    Hernandez I; Zhang Y
    J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium.
    Gielen E; Aldvén M; Kanis JA; Borgström F; Senior E; Willems D
    Osteoporos Int; 2024 Jul; 35(7):1173-1183. PubMed ID: 38565690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
    O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
    Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
    Liu J; Guo H; Rai P; Pinto L; Barron R
    Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
    Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
    Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.
    Agarwal AR; Kinnard MJ; Murdock C; Zhao AY; Ahiarakwe U; Cohen JS; Moseley KF; Golladay GJ; Thakkar SC
    Osteoporos Int; 2024 Jul; 35(7):1223-1229. PubMed ID: 38619605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
    Le QA; Hay JW; Becker R; Wang Y
    Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
    Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
    BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.
    Boytsov N; Zhang X; Sugihara T; Taylor K; Swindle R
    Curr Med Res Opin; 2015; 31(9):1665-75. PubMed ID: 26121328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.
    Liu J; Laster A; Xu X; Guo H; Oates M; Gandra SR
    J Bone Miner Res; 2021 Dec; 36(12):2309-2316. PubMed ID: 34490946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis.
    Zhong Q; Liao Y; Zou W
    Altern Ther Health Med; 2024 Aug; 30(8):258-263. PubMed ID: 38064598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
    Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
    Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
    Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
    Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans.
    LaFleur J; DuVall SL; Willson T; Ginter T; Patterson O; Cheng Y; Knippenberg K; Haroldsen C; Adler RA; Curtis JR; Agodoa I; Nelson RE
    Bone; 2015 Sep; 78():174-85. PubMed ID: 25896952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.